辉瑞-话题@MedSci

#辉瑞#

21篇内容 | 4857人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2212272, encodeId=896822122e2c8, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a> <a href='/topic/show?id=419a105085b1' target=_blank style='color:#2F92EE;'>#RSV疫苗#</a>, objectTitle=辉瑞拿下英国500万剂RSV疫苗超级订单, objectType=article, longId=832195, objectId=3e24832195d5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240628/26a4e82bbdf84c099e62d201fabb00e3-GeZnBzQ1CO7P.jpg, objectUrl=/article/show_article.do?id=3e24832195d5, replyNumber=0, likeNumber=83, createdTime=2024-06-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=3e24832195d5, moduleTitle=辉瑞拿下英国500万剂RSV疫苗超级订单, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e24832195d5)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2166773, encodeId=06202166e73da, content=<a href='/topic/show?id=a77610e36937' target=_blank style='color:#2F92EE;'>#PROTAC降解剂#</a><a href='/topic/show?id=62d710e370a2' target=_blank style='color:#2F92EE;'>#Vepdegestrant#</a>对ER+/HER2-晚期<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者有明显获益.<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a> , objectTitle=PROTAC降解剂Vepdegestrant对ER+/HER2-晚期乳腺癌患者有明显获益, objectType=article, longId=798978, objectId=13bae9897857, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20231023/dcfd9dda519542f4a491b562784ca46d.jpg, objectUrl=/article/show_article.do?id=13bae9897857, replyNumber=0, likeNumber=135, createdTime=2023-11-05, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=13bae9897857, moduleTitle=PROTAC降解剂Vepdegestrant对ER+/HER2-晚期乳腺癌患者有明显获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13bae9897857)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2140711, encodeId=b7d22140e1196, content=<a href='/topic/show?id=f336e29134' target=_blank style='color:#2F92EE;'>#FDA#</a>已批准<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a><a href='/topic/show?id=0daf39e120a' target=_blank style='color:#2F92EE;'>#呼吸道合胞病毒#</a>（RSV）二价<a href='/topic/show?id=419a105085b1' target=_blank style='color:#2F92EE;'>#RSV疫苗#</a> <a href='/topic/show?id=dd0d1063109e' target=_blank style='color:#2F92EE;'>#Abrysvo#</a>（RSVpreF，PF-06928316）上市，未来会竞争十分激烈, objectTitle=FDA已批准辉瑞呼吸道合胞病毒（RSV）二价疫苗 Abrysvo（RSVpreF，PF-06928316）上市, objectType=article, longId=775173, objectId=bbfee7517321, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230603/77e7153aca4749b4b1c18c92d4ee87da.jpg, objectUrl=/article/show_article.do?id=bbfee7517321, replyNumber=0, likeNumber=170, createdTime=2023-06-04, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=bbfee7517321, moduleTitle=FDA已批准辉瑞呼吸道合胞病毒（RSV）二价疫苗 Abrysvo（RSVpreF，PF-06928316）上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbfee7517321)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2137987, encodeId=db5b213e9872a, content=单剂量<a href='/topic/show?id=8d9f15481b0' target=_blank style='color:#2F92EE;'>#rimegepant#</a><a href='/topic/show?id=592310602427' target=_blank style='color:#2F92EE;'>#瑞美吉泮#</a>能快速缓解<a href='/topic/show?id=1ffc2e613ae' target=_blank style='color:#2F92EE;'>#偏头痛#</a>急性发作，这次是在中韩两国开展的临床试验，可能主要是为了在中国和韩国上市使用，中韩都是亚洲人群，这个药物是第一个CGRP类药物，因此，CDE可能要求补充一个临床3期临床试验结果。最终结果表明，亚洲人与欧美并无区别，疗效几乎完全一致！！这可能为后面其它的CGRP类药物上市铺平道路，其它的<a href='/topic/show?id=5e6e1062606b' target=_blank style='color:#2F92EE;'>#CGRP类药物#</a>在国内上市，可能就无需这么复杂了。当然，偏头痛这类新药出现，<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a>制药可能是大赢家！不管是小分子，还是<a href='/topic/show?id=f7bd103431f8' target=_blank style='color:#2F92EE;'>#鼻喷剂#</a><a href='/topic/show?id=a6c1105e74ed' target=_blank style='color:#2F92EE;'>#Zavegepant#</a>，都极具治疗潜力！, objectTitle=Lancet Neuro：单剂量rimegepant能快速缓解偏头痛急性发作, objectType=article, longId=772841, objectId=7d40e72841c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d40e72841c2, replyNumber=0, likeNumber=159, createdTime=2023-05-20, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7d40e72841c2, moduleTitle=Lancet Neuro：单剂量rimegepant能快速缓解偏头痛急性发作, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d40e72841c2)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2126336, encodeId=67fd2126336cc, content=好奇<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a> <a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a><a href='/topic/show?id=d61a9261957' target=_blank style='color:#2F92EE;'>#赛诺菲#</a><a href='/topic/show?id=e0df9e832a7' target=_blank style='color:#2F92EE;'>#阿斯利康#</a><a href='/topic/show?id=4c2ce960918' target=_blank style='color:#2F92EE;'>#罗氏#</a><a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>这些大公司在中国的知名度，看看它们的围观人数，是不是成正比！, objectTitle=辉瑞, objectType=topic, longId=93725, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=1, likeNumber=171, createdTime=2023-04-16, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=香港, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2126335, encodeId=bd29212633551, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a><a href='/topic/show?id=6dbf10589ea2' target=_blank style='color:#2F92EE;'>#CD3/BCMA双抗#</a><a href='/topic/show?id=8ecd10589883' target=_blank style='color:#2F92EE;'>#Elranatamab#</a>治疗<a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a><a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=ASH 2022：辉瑞CD3/BCMA双抗Elranatamab治疗RRMM结果公布, objectType=article, longId=751741, objectId=209ee51741ba, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221123/bea5c122810c404a8ba7de429c8571e3.jpg, objectUrl=/article/show_article.do?id=209ee51741ba, replyNumber=0, likeNumber=158, createdTime=2023-04-16, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=香港, moduleDTOList=[ModuleDTO(moduleId=209ee51741ba, moduleTitle=ASH 2022：辉瑞CD3/BCMA双抗Elranatamab治疗RRMM结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=209ee51741ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2117688, encodeId=8000211e6883e, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a><a href='/topic/show?id=b62de4996a1' target=_blank style='color:#2F92EE;'>#科研#</a>, objectTitle=辉瑞：临床系列公开课, objectType=open_course, longId=2544, objectId=2544, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221128/1669630169940_6459136.png, objectUrl=https://open.medsci.cn/study/4f27f525447c3, replyNumber=0, likeNumber=117, createdTime=2023-03-05, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4f27f525447c3, moduleTitle=辉瑞：临床系列公开课, moduleType=open_course, hrefUrl=https://open.medsci.cn/study/4f27f525447c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2115330, encodeId=82392115330b1, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a>学习, objectTitle=辉瑞：临床系列公开课, objectType=course, longId=2544, objectId=2544, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221128/1669630169940_6459136.png, objectUrl=https://class.medsci.cn/study/4f27f525447c3, replyNumber=0, likeNumber=85, createdTime=2023-02-18, rootId=0, userName=ms2000000548072957, userId=86638367415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=内蒙古, moduleDTOList=[ModuleDTO(moduleId=4f27f525447c3, moduleTitle=辉瑞：临床系列公开课, moduleType=course, hrefUrl=https://class.medsci.cn/study/4f27f525447c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2093710, encodeId=b7072093e105b, content=<a href='/topic/show?id=68ca828e57' target=_blank style='color:#2F92EE;'>#GSK#</a>老年人<a href='/topic/show?id=0daf39e120a' target=_blank style='color:#2F92EE;'>#呼吸道合胞病毒#</a>（RSV）<a href='/topic/show?id=62afe048720' target=_blank style='color:#2F92EE;'>#疫苗#</a>三期临床成功，重症保护率94.1%。最接近的竞争对手<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a>（Pfizer）表示，其 <a href='/topic/show?id=2e241049515d' target=_blank style='color:#2F92EE;'>#RSVpreF疫苗#</a>的第三阶段 RENOIR 研究的中期结果显示，疫苗对患有更严重疾病的参与者的有效性为 85.7%。, objectTitle=GSK老年人呼吸道合胞病毒（RSV）疫苗三期临床成功，重症保护率94.1%, objectType=article, longId=743299, objectId=ff46e4329998, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221009/a428c54932554ae0af3adbc7bcfc9d52.jpg, objectUrl=/article/show_article.do?id=ff46e4329998, replyNumber=0, likeNumber=147, createdTime=2022-10-14, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff46e4329998, moduleTitle=GSK老年人呼吸道合胞病毒（RSV）疫苗三期临床成功，重症保护率94.1%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff46e4329998)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1249647, encodeId=b62d124964eff, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a>/BioNtech、<a href='/topic/show?id=1b27120e0ed' target=_blank style='color:#2F92EE;'>#Moderna#</a>的竞争焦点已经转移到<a href='/topic/show?id=c05410448921' target=_blank style='color:#2F92EE;'>#Omicron#</a>变异株，几乎同时递交了Omicron BA.4/5变异株特异性<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>的上市申请。国内方面，<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>的竞争同样转移到Omicron变异株，国药中生、<a href='/topic/show?id=b7abe328570' target=_blank style='color:#2F92EE;'>#石药集团#</a>、艾博生物、<a href='/topic/show?id=159a104e4091' target=_blank style='color:#2F92EE;'>#斯微生物#</a>等已经纷纷进入临床阶段。, objectTitle=Moderna递交Omicron特异性mRNA疫苗mRNA-1273.222紧急使用授权申请, objectType=article, longId=736906, objectId=625fe3690684, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220823/42da8b14703742aeba9f546e3518e030.jpg, objectUrl=/article/show_article.do?id=625fe3690684, replyNumber=0, likeNumber=204, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=625fe3690684, moduleTitle=Moderna递交Omicron特异性mRNA疫苗mRNA-1273.222紧急使用授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=625fe3690684)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1249454, encodeId=a655124945458, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a><a href='/topic/show?id=a4b1104e23d0' target=_blank style='color:#2F92EE;'>#Ervogastat#</a>/<a href='/topic/show?id=4154104e245b' target=_blank style='color:#2F92EE;'>#Clesacostat#</a>用于<a href='/topic/show?id=2fdc99e222d' target=_blank style='color:#2F92EE;'>#非酒精性脂肪性肝炎#</a>, objectTitle=FDA授予辉瑞Ervogastat/Clesacostat用于非酒精性脂肪性肝炎 (NASH) 的快速通道资格, objectType=article, longId=728015, objectId=c099e2801596, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220525/32ac43ffcf0b4256bf6df38a6cb9937d.jpg, objectUrl=/article/show_article.do?id=c099e2801596, replyNumber=0, likeNumber=126, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c099e2801596, moduleTitle=FDA授予辉瑞Ervogastat/Clesacostat用于非酒精性脂肪性肝炎 (NASH) 的快速通道资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c099e2801596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1249453, encodeId=86bc124945353, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a>, objectTitle=2022全球制药50强：辉瑞重回王座，新冠助力！中国药企离20强还有多远？, objectType=article, longId=729135, objectId=3e7ce2913545, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220608/39a02f9a928c4532884f9bd0ff71358b.jpg, objectUrl=/article/show_article.do?id=3e7ce2913545, replyNumber=0, likeNumber=118, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e7ce2913545, moduleTitle=2022全球制药50强：辉瑞重回王座，新冠助力！中国药企离20强还有多远？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e7ce2913545)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1249452, encodeId=e55c12494524f, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a>、<a href='/topic/show?id=1b27120e0ed' target=_blank style='color:#2F92EE;'>#Moderna#</a><a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>幼儿适应症, objectTitle=FDA委员会全票支持！辉瑞、Moderna新冠疫苗幼儿适应症即将获批, objectType=article, longId=729773, objectId=2db7e297734b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220608/b8cb55b0e7e548fa84f62a7ec29b4b17.jpg, objectUrl=/article/show_article.do?id=2db7e297734b, replyNumber=0, likeNumber=163, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2db7e297734b, moduleTitle=FDA委员会全票支持！辉瑞、Moderna新冠疫苗幼儿适应症即将获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2db7e297734b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1249451, encodeId=c049124945135, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a>的<a href='/topic/show?id=9b231044e849' target=_blank style='color:#2F92EE;'>#Paxlovid#</a>, objectTitle=辉瑞新冠口服药Paxlovid用于暴露后预防的II/III期临床失败, objectType=article, longId=725951, objectId=a6bfe25951ed, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220424/9fe324e8e07c44bab6913054682b272e.jpg, objectUrl=/article/show_article.do?id=a6bfe25951ed, replyNumber=0, likeNumber=125, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6bfe25951ed, moduleTitle=辉瑞新冠口服药Paxlovid用于暴露后预防的II/III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6bfe25951ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1208608, encodeId=18471208608af, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a><a href='/topic/show?id=1ffc2e613ae' target=_blank style='color:#2F92EE;'>#偏头痛#</a>, objectTitle=辉瑞和 Biohaven 获得欧盟委员会对偏头痛药物 Vydura 的认可, objectType=article, longId=299740, objectId=7dce299e40a2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2022227/1645948077699_5295902.png, objectUrl=/article/show_article.do?id=7dce299e40a2, replyNumber=0, likeNumber=162, createdTime=2022-04-04, rootId=0, userName=医者仁者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7dce299e40a2, moduleTitle=辉瑞和 Biohaven 获得欧盟委员会对偏头痛药物 Vydura 的认可, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7dce299e40a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1208607, encodeId=0060120860e13, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a><a href='/topic/show?id=567041e8055' target=_blank style='color:#2F92EE;'>#基因治疗#</a><a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a>, objectTitle=辉瑞的DMD基因疗法fordadistrogene movaparvovec在患者死亡后被FDA搁置, objectType=article, longId=292791, objectId=e037292e9125, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20211226/1640491463192_5295902.png, objectUrl=/article/show_article.do?id=e037292e9125, replyNumber=0, likeNumber=173, createdTime=2022-04-04, rootId=0, userName=医者仁者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e037292e9125, moduleTitle=辉瑞的DMD基因疗法fordadistrogene movaparvovec在患者死亡后被FDA搁置, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e037292e9125)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1208606, encodeId=14fc120860653, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a>, objectTitle=EMA建议对辉瑞的Paxlovid进行有条件授权, objectType=article, longId=295113, objectId=1cec29511340, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202223/1643892552293_5295902.png, objectUrl=/article/show_article.do?id=1cec29511340, replyNumber=0, likeNumber=145, createdTime=2022-04-04, rootId=0, userName=医者仁者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cec29511340, moduleTitle=EMA建议对辉瑞的Paxlovid进行有条件授权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1cec29511340)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1071685, encodeId=065110e1685c4, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a>, objectTitle=新研究！辉瑞新冠疫苗或能预防印度变异病毒, objectType=article, longId=212196, objectId=426b212196c8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/270718015_90777890.jpg, objectUrl=/article/show_article.do?id=426b212196c8, replyNumber=0, likeNumber=345, createdTime=2021-11-19, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=426b212196c8, moduleTitle=新研究！辉瑞新冠疫苗或能预防印度变异病毒, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=426b212196c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1004058, encodeId=017a100405818, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a>, objectTitle=辉瑞/ BioNTech COVID-19疫苗的真实世界证据, objectType=article, longId=208451, objectId=1d6420845140, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021315/1615810723212_5295902.jpeg, objectUrl=/article/show_article.do?id=1d6420845140, replyNumber=0, likeNumber=408, createdTime=2021-07-30, rootId=0, userName=小小医者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d6420845140, moduleTitle=辉瑞/ BioNTech COVID-19疫苗的真实世界证据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d6420845140)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=898630, encodeId=8fa889863081, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>国内<a href='/topic/show?id=62afe048720' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=62afe048720' target=_blank style='color:#2F92EE;'>#疫苗#</a></a><a href='/topic/show?id=ea112303079' target=_blank style='color:#2F92EE;'>#临床试验#</a>整体水平确实低于<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a>这些巨头，我们的<a href='/topic/show?id=62afe048720' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=62afe048720' target=_blank style='color:#2F92EE;'>#疫苗#</a></a>试验开始早，但是结果出来慢，这与研究设计关联较大。我们的设计中没有看到<a href='/topic/show?id=8c4360e8858' target=_blank style='color:#2F92EE;'>#期中分析#</a>的结果，而辉瑞此次公布的是期中分析的结果。这是国人需要努力的地方，<a href='/topic/show?id=925fe34453b' target=_blank style='color:#2F92EE;'>#研究设计#</a>能力需要提升, objectTitle=2020年11月12日全球新冠肺炎（COVID-19）疫情简报，确诊超5237万，中国国药疫苗数据好于预期, objectType=article, longId=203286, objectId=0014203286a7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20201009/8fa5f3e31e68414ea78defc7b044e57a.png, objectUrl=/article/show_article.do?id=0014203286a7, replyNumber=1, likeNumber=1240, createdTime=2020-11-12, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0014203286a7, moduleTitle=2020年11月12日全球新冠肺炎（COVID-19）疫情简报，确诊超5237万，中国国药疫苗数据好于预期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0014203286a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

辉瑞

2020-05-29发表于威斯康星

梅斯管理员 (审核中...)

前往app查看评论内容

#辉瑞# #RSV疫苗#

辉瑞拿下英国500万剂RSV疫苗超级订单

2024-06-29发表于加利福尼亚

侠胆医心 (审核中...)

前往app查看评论内容

#PROTAC降解剂##Vepdegestrant#对ER+/HER2-晚期#乳腺癌#患者有明显获益.#辉瑞#

PROTAC降解剂Vepdegestrant对ER+/HER2-晚期乳腺癌患者有明显获益

2023-11-05发表于威斯康星

侠胆医心 (审核中...)

前往app查看评论内容

#FDA#已批准#辉瑞##呼吸道合胞病毒#（RSV）二价#RSV疫苗# #Abrysvo#（RSVpreF，PF-06928316）上市，未来会竞争十分激烈

FDA已批准辉瑞呼吸道合胞病毒（RSV）二价疫苗 Abrysvo（RSVpreF，PF-06928316）上市

2023-06-04发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

全文收起单剂量#rimegepant##瑞美吉泮#能快速缓解#偏头痛#急性发作，这次是在中韩两国开展的临床试验，可能主要是为了在中国和韩国上市使用，中韩都是亚洲人群，这个药物是第一个CGRP类药物，因此，CDE可能要求补充一个临床3期临床试验结果。最终结果表明，亚洲人与欧美并无区别，疗效几乎完全一致！！这可能为后面其它的CGRP类药物上市铺平道路，其它的#CGRP类药物#在国内上市，可能就无需这么复杂了。当然，偏头痛这类新药出现，#辉瑞#制药可能是大赢家！不管是小分子，还是#鼻喷剂##Zavegepant#，都极具治疗潜力！

Lancet Neuro：单剂量rimegepant能快速缓解偏头痛急性发作

2023-05-20发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

好奇#辉瑞# #诺华##赛诺菲##阿斯利康##罗氏##杨森#这些大公司在中国的知名度，看看它们的围观人数，是不是成正比！

2023-04-16发表于香港

侠胆医心 (审核中...)

前往app查看评论内容

#辉瑞##CD3/BCMA双抗##Elranatamab#治疗#RRMM##多发性骨髓瘤#

ASH 2022：辉瑞CD3/BCMA双抗Elranatamab治疗RRMM结果公布

2023-04-16发表于香港

lifestar (审核中...)

前往app查看评论内容

#辉瑞##科研#

辉瑞：临床系列公开课

2023-03-05发表于上海

ms2000000548072957 (审核中...)

前往app查看评论内容

#辉瑞#学习

辉瑞：临床系列公开课

2023-02-18发表于内蒙古

lifestar (审核中...)

前往app查看评论内容

#GSK#老年人#呼吸道合胞病毒#（RSV）#疫苗#三期临床成功，重症保护率94.1%。最接近的竞争对手#辉瑞#（Pfizer）表示，其 #RSVpreF疫苗#的第三阶段 RENOIR 研究的中期结果显示，疫苗对患有更严重疾病的参与者的有效性为 85.7%。

GSK老年人呼吸道合胞病毒（RSV）疫苗三期临床成功，重症保护率94.1%

2022-10-14

小小医者 (审核中...)